STING1 and pancreatic neoplasm: Our previous work has also shown that the STING pathways of advanced pancreatic tumor cell lines are defective enough such that negligible type‐I IFN are induced even when treated with 2′3′‐cGAMP, a membrane‐impermeable STING agonist [28].